Angiotensin converting enzyme (ACE) inhibitors have been shown to improve survival and to
reduce the risk of cardiovascular events in some groups of patients following myocardial
infarction. This study is designed to test whether early initiation (≤7 days) of an ACE
inhibitor post-coronary artery bypass graft (CABG), would reduce cardiovascular events. The
trial was a double-blind, placebo controlled study of 2,553 patients randomly assigned to
quinapril, target dose 40 mg daily or placebo, followed up to 43 months.